BI 836826

DRUG6 trials

Sponsors

Boehringer Ingelheim, Gilead Sciences

Conditions

Chronic Lymphocytic Leukemia (CLL)Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Phase 1

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

CompletedNCT01296932

Boehringer IngelheimLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2011-02-11End: 2017-07-10Updated: 2020-08-20

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

CompletedNCT01403948

Boehringer IngelheimLymphoma, Non-Hodgkin

Start: 2011-08-01End: 2018-02-28Updated: 2020-08-11

Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia

TerminatedNCT02538614

Gilead SciencesChronic Lymphocytic Leukemia (CLL)

Start: 2015-12-29End: 2017-07-05Updated: 2020-11-25

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

CompletedNCT02759016

Boehringer IngelheimLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2016-06-23End: 2019-07-09Updated: 2020-09-29

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

WithdrawnNCT03343678

Boehringer IngelheimLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2018-01-17End: 2020-11-25Updated: 2018-01-09

Phase 2

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

CompletedNCT02624492

Boehringer IngelheimLymphoma, Large B-Cell, Diffuse

Start: 2016-01-28End: 2018-03-16Updated: 2019-06-17

Related Papers

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Investigational New Drugs2021-02-017 citations

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

2020-03-148 citations